The multifaceted contribution of p53 to the anti-cancer immune response provides numerous therapeutic targets in cancers with mutated p53 and an immunosuppressed TME, however these targets likely vary depending on the type of cancer and p53 mutation. This evidence concerns the gene TP53 and cancer.